6489 LOGO20THELANSIS 12

According to a literature survey, The total age-adjusted annual incidence rate was 60/100,000, with the highest incidence in the first year of life 120 to 135 per 100,000, Focal epilepsies or epileptic syn-dromes 35 to 40 per 100,000population. The generalized incidence rate is 24/100,000 and 3% incidence rate, 2/100,000 of the epilepsies or epileptic syndromes. The rate of idiopathic EE is 29 per 100,000 and symptomatic or cryptogenic epilepsies is 30/ 100,000.

Read more:- Epileptic Encephalopathies (EE) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Epileptic-Encephalopathies-EE-forecast

Comprehensive insight on patient segmentation based on age, sex, classification (Neonatal period, Infancy, Childhood & Others), seizure types (Tonic, Focal, Myoclonic, and others), Biomarker segmentation (SCN1A, SCN2A, SCN3A, and SCN8A )Signs & Symptoms, Clini-cal Manifestations, Treatment types (Opiates, Anticonvulsant medications, Antidepressants, and others) has been provided into the epidemiology section of the Epileptic Encephalopathy(EE) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

KOL database for PMR

In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Bial – Portela C S.A., Marinus Pharmaceuticals, Xenon Pharmaceuticals Inc., MGC Pharmaceuticals d.o.o, UCB Pharma, Abbott, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., GlaxoSmithKline, GW Research Ltd, Stoke Therapeutics, Inc,

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Rosacea – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Menorrhagia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Anaplastic large cell lymphoma (ALCL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Lymphangiomyomatosis (LAM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Fibrolamellar Carcinoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

[email protected]

[email protected]

Tags: Epileptic Encephalopathies (EE), Epileptic Encephalopathies (EE) market outlook report, Epileptic Encephalopathies (EE) competitive landscape, Epileptic Encephalopathies (EE) market forecast